Melbourne, Australia — 27th February 2026
Longevity Life Sciences (LLS) today announced that CellVive NMN® is now available in Chemist Warehouse stores nationwide, marking the first time Nicotinamide Mononucleotide (NMN) has been accessible through Australia’s leading retail pharmacy network.
The launch introduces a new category to Australian consumers, with leading complementary medicine brands Melrose FutureLabs, Wanderlust BioHack, Bioglan and Nature’s Way releasing NMN formulations powered by CellVive NMN®, the first NMN ingredient permitted for use in TGA-listed complementary medicines.
NMN was added to the Therapeutic Goods (Permissible Ingredients) Determination in December 2025, enabling its inclusion in listed medicines in Australia.
LLS is the exclusive distributor of NMN in Australia under the trading name CellVive NMN®.
A National Retail Milestone for Longevity Science
This nationwide rollout represents a defining moment in the translation of longevity science into regulated, pharmacy-grade products.
Through Chemist Warehouse’s national footprint, Australian consumers can now access:
- Melrose FutureLabs NMN capsules and powder
- Wanderlust BioHack NMN range
- Bioglan NMN capsules
- Nature’s Way NMN combination formula
All formulated with CellVive NMN® and listed on the ARTG.
Together, these launches establish the first regulated NMN retail ecosystem in the world at scale.
Setting a Global Regulatory Benchmark
Australia is now recognised as one of the first countries to create a clear, compositional and regulatory pathway for NMN in complementary medicines.
This framework defines identity, purity and quality requirements, ensuring pharmacy-grade supply chain control and enabling compliant consumer access through listed medicines.
The result is a category built on scientific, manufacturing and regulatory integrity, rather than unregulated direct-to-consumer supply.
Industry Collaboration to Build a New Health Category
The Chemist Warehouse rollout reflects a coordinated effort across research, regulation, manufacturing and retail.
By partnering with established complementary medicine brands, LLS has enabled rapid national access while maintaining a single, controlled pharmaceutical-grade ingredient supply.
This model supports category education at scale, providing pharmacists with a compliant NMN pathway, whilst creating consumer confidence through trusted retail channels.
Executive Commentary
Sally Panton, Co-Founder & CEO of Longevity Life Sciences, said:
“Today marks the transition of NMN from a research breakthrough into a regulated, pharmaceutical-grade health solution. Seeing CellVive NMN® available nationwide in Chemist Warehouse with some of the country’s most respected health brands is a defining moment — not only for our company, but for the future of preventive and precision health.”
Lucy Canny, Co-Founder & Chief Operating Officer, Longevity Life Sciences, said:
“This launch reflects years of work across scientific validation, regulatory leadership and supply-chain development to ensure Australians can access NMN in a compliant, pharmacy-grade format.”
About CellVive NMN®
CellVive NMN® is the first NMN ingredient permitted for use in TGA-listed complementary medicines. Exclusively distributed in Australia by Longevity Life Sciences and manufactured to pharmaceutical-grade quality standards.
It enables the development of regulated NMN products listed on the Australian Register of Therapeutic Goods (ARTG).
About Longevity Life Sciences
Longevity Life Sciences is an Australian biotechnology and consumer health company dedicated to translating longevity science into clinically validated, regulated and scalable health solutions.
